JPM vs RAPP · P/E 14, rev $57.35B vs rev $20.0M
JPMorgan Chase & Co (JPM) versus Rapport Therapeutics, Inc. Common Stock (RAPP) — a side-by-side from cached financials, not a winner call.
JPMorgan Chase & Co (JPM) is a banks - diversified company listed on US. It is led by Jamie Dimon.
Rapport Therapeutics, Inc. Common Stock (RAPP) is a biotechnology company listed on US.
Latest reported JPM revenue for 2026-06-30 was $57.35B. Net income was $21.16B. Revenue was up 15.1% from 2026-03-31 to 2026-06-30. JPM currently screens at market cap $805.69B and trailing P/E 14.2.
Latest reported RAPP revenue for 2026-06-30 was $20.0M. Net income was -$76.5M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. RAPP currently screens at market cap $532.9M.
JPM currently screens at market cap $805.69B and trailing P/E 14.2. RAPP currently screens at market cap $532.9M.
Not investment advice. Open the JPM and RAPP stock pages for the full models.
Not investment advice.